Skip to main content
ZEVRA THERAPEUTICS, INC. logo

ZEVRA THERAPEUTICS, INC. — Investor Relations & Filings

Ticker · ZVRA ISIN · US4884452065 LEI · 254900CU6T74V18Y1W18 US Manufacturing
Open in API
Filings indexed 830 across all filing types
Latest filing 2023-03-06 Proxy Solicitation & In…
Country US United States of America
Listing US ZVRA

About ZEVRA THERAPEUTICS, INC.

https://zevra.com/

Zevra Therapeutics, Inc. is a commercial-stage biopharmaceutical company dedicated to developing and commercializing therapies for patients with rare diseases. The company focuses on addressing significant unmet medical needs by combining a data-driven scientific approach with a patient-first perspective. Its portfolio includes commercial products such as MIPLYFFA®, an FDA-approved treatment for Niemann-Pick disease type C (NPC), and OLPRUVA®. Zevra Therapeutics also maintains a late-stage clinical pipeline, specializing in advancing promising medicines that face complex clinical and regulatory challenges for conditions with limited or no available treatments.

Recent filings

Filing Released Lang Actions
Proxy Solicitation & Information Statement 2023
Proxy Solicitation & Information Statement Classification · 100% confidence The document is a Schedule 14A Proxy Statement filed with the SEC, which is used to solicit shareholder votes for an upcoming Annual Meeting of Stockholders. It includes detailed information about the matters to be voted on, such as election of directors, ratification of the independent auditor, and shareholder proposals. The document is not the Annual Report itself, nor is it a voting results announcement or a report publication announcement. It is a proxy solicitation document intended to inform shareholders and request their votes. According to the filing definitions, this matches the category 'Proxy Solicitation & Information Statement' (PSI). The document length and content confirm it is a full proxy statement, not a brief notice or announcement.
2023-03-06 English
Regulatory Filings 2023
Regulatory Filings Classification · 95% confidence The document is a correspondence letter from Zevra Therapeutics, Inc. to the SEC staff regarding comments on a Preliminary Proxy Statement on Schedule 14A filed on February 27, 2023. The letter addresses SEC staff comments and the company's responses about disclosures required in the proxy statement, such as stockholder proposals, director nominations, and voting effects. The document does not contain the proxy statement itself but discusses revisions to it. The length is 3587 characters, which is relatively short and consistent with a comment response letter rather than a full report. This type of document is best classified as a Regulatory Filing (RNS) because it is a regulatory correspondence related to a proxy statement filing, not the proxy statement itself or a definitive report.
2023-03-06 English
Regulatory Filings 2023
Regulatory Filings Classification · 60% confidence The provided document text appears to be encoded or encrypted and does not contain any readable content, keywords, regulatory headers, or references to specific report types, fiscal periods, or regulatory bodies. Without any discernible information or context, it is impossible to classify the document as a specific financial filing type. According to the fallback rule, when a document does not fit any specific category or lacks sufficient information, it should be classified as a Regulatory Filing (RNS). The document length is 15,000 characters, which is substantial, but the content is not interpretable. Therefore, the best classification is RNS with moderate confidence due to lack of content clarity.
2023-03-03 English
DFAN 14A
Proxy Solicitation & Information Statement
2023-03-03 English
PREN14A
Proxy Solicitation & Information Statement Classification · 100% confidence The document is titled 'PREN14A' and is identified as a 'Preliminary Proxy Statement' pursuant to Schedule 14A under the Securities Exchange Act of 1934. It is related to the solicitation of proxies for the 2023 Annual Meeting of Stockholders of Zevra Therapeutics, Inc. The content includes detailed information about nominees for the board of directors, proposals to repeal bylaws, voting instructions, and background of the solicitation. This matches the description of Proxy Solicitation & Information Statement filings, which are materials sent to shareholders to provide information and request votes for meetings. The document is not an Annual Report, Earnings Release, or other financial report, but specifically a proxy statement for shareholder voting purposes.
2023-03-03 English
FORM DEFA14A
Remuneration Information Classification · 100% confidence The document is a Form DEFA14A, which is a definitive additional proxy solicitation material filed pursuant to Schedule 14A under the Securities Exchange Act of 1934. It includes detailed information about the company's upcoming annual meeting of stockholders, director nominations, and proxy solicitation efforts. The text references a preliminary proxy statement and discusses board nominations and shareholder proposals, which are typical contents of proxy solicitation materials. The document is not an annual report, earnings release, or other financial report but rather materials related to proxy solicitation and shareholder voting. Therefore, the appropriate classification is Remuneration Information (DEF 14A), which covers proxy statements and related materials.
2023-02-27 English

Browse filings by year

18 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.